Navigation Links
Pappas Ventures Names Pat Gage to Scientific Advisory Board
Date:7/9/2012

RESEARCH TRIANGLE PARK, N.C., July 9, 2012 /PRNewswire/ -- Pappas Ventures today announced the appointment of L. Patrick (Pat) Gage, PhD to the company's Scientific Advisory Board (SAB).  Dr. Gage has extensive experience in the biotech and pharmaceutical industry, including previously-held senior positions at Hoffmann-La Roche, Genetics Institute and Wyeth (now Pfizer).  Throughout his career, he oversaw the development of more than a dozen marketed biologics and vaccines, as well as several small molecule drugs.

"We are thrilled to have Pat on our team," said Art Pappas, Managing Partner of Pappas Ventures. "His drug development experience will be invaluable to our portfolio companies and his insight in identifying trends and opportunities in the life sciences industry should further enhance our firm's role as a value-added investor."

During his 18-year career at Hoffmann-La Roche, Dr. Gage held several leadership roles in research management, including service as Vice President of Exploratory Research, which was responsible for U.S. drug discovery. Dr. Gage then joined Genetics Institute, Inc. in 1989 and ultimately served as President after Wyeth (now Pfizer) acquired the company. He was then named President of Wyeth Research, taking responsibility for global pharmaceutical and vaccine R&D, as well as global biopharmaceutical manufacturing.

Dr. Gage founded enGage Biotech Consulting in 2003 to focus on guiding the development of new biopharmaceutical products and companies. In addition to his consulting work, he currently serves as Chairman of Cytokinetics, Inc. and Chairman of Tetraphase Pharmaceuticals.  He previously was Chairman and subsequently Interim CEO of PDL BioPharma, and was Chairman of Adnexus Therapeutics.

"I am delighted to join Pappas Ventures' SAB. The fund's investments mirror my interest in assisting in the development of high-impact pharmaceutical products."

About Pappas Ventures

Founded in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures. Pappas Ventures has more than $350 million in capital under management, and has guided the launch and/or development of more than 50 companies, including Plexxikon Inc. (acquired by Daiichi Sankyo), Cerexa (acquired by Forest Laboratories), Peninsula Pharmaceuticals (acquired by Johnson & Johnson), Syntonix (acquired by Biogen IDEC), NuVasive (IPO), and Arena Pharmaceuticals (IPO). Most recently, its portfolio company Tesaro conducted a successful initial public offering. For more information about Pappas Ventures and for further information about Pat Gage and the rest of our distinguished Scientific Advisory Board, please visit www.pappasventures.com.

CONTACT: Kimberly Hofman-McEnaney khmcenaney@capstrat.com 919-745-3652


'/>"/>
SOURCE Pappas Ventures
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunpeaks Ventures Files Defamation Lawsuit
2. Practice Fusion Announces $34 Million in Financing Led by Artis Ventures
3. DiversityInc Names Lilly a Top Company for Diversity
4. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
5. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
6. myMatrixx Names Craig Rollins, Vice President of Ancillary and Business Development
7. Bausch + Lomb Names John Barr Global President Surgical
8. Forbes Names Pharmalot, a UBM Canon Pharmaceutical Media Group Brand, as a Top Social Media Influencer
9. Wake Forest Baptist Names President of Piedmont Triad Research Park and Chief Innovation Officer
10. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
11. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
(Date:12/2/2016)... December 2, 2016 According ... Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology ... Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to ... valued at USD 60.22 Billion in 2016. This ... of 5.5% during the forecast period (2016-2021) to ...
(Date:12/2/2016)... , Dec. 2, 2016  The Addiction Treatment ... Academy of Managed Care Pharmacy (AMCP), has released ... better address the opioid addiction crisis, including through ... (MAT). ATAG,s newly released paper, "The ... to Naloxone," addresses many issues around gaps and ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Center for ... for caregivers of those affected by autism spectrum disorder (ASD) and other developmental disabilities. ... Seals Maine, will give parents and other caregivers the opportunity to share stories and ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... U.S. Surgeon ... interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at ... learned that medicine is about more than making diagnoses and prescribing medicine,” he states. ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... ... 02, 2016 , ... More than half of American teens report losing their ... speaking with their child about sex related topics, less than 60 percent spoke about ... to announce the launch of its second edition of the “Sexual Wellness” campaign, aiming ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, ... through labeling, storing, shipping and disposal. The new version is a faster and ...
Breaking Medicine News(10 mins):